Why the study?
Splenic hemangioendothelioma is an extremely rare vascular tumor with uncertain malignant potential, and treatment experience is limited due to its rare occurrence.
Thalidomide may slow disease progression in patients with relapsed or metastatic splenic hemangioendothelioma.
No takes yet. Share an insight, caveat, or question.
Case of splenic HE adds to sparse literature; leaves open optimal management strategies for this rare tumor.
Chen et al. (2019) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: